Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2CNS 1

Conditions

Neoplasms 2Glioblastoma 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × CT-322 × Clear all
NCT01146171 2012-02-07

Japanese Phase 1 Study of BMS-844203 (CT322)

Bristol-Myers Squibb

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT00768911 2010-10-27

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 1 Unknown
30 enrolled
CNS

Glioblastoma

NCT00374179 2009-02-24

CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 1 Completed
40 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡